Multiple Myeloma

J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
Fierce Pharma
CAR-T
Bristol Myers Squibb
JNJ
Legend Biotech
AACR
Multiple Myeloma
Carvykti
Abecma
Flag link:
Caribou gets FDA fast track for allogeneic CAR-T
Caribou gets FDA fast track for allogeneic CAR-T
Biopharma Reporter
Caribou Biosciences
FDA
Multiple Myeloma
CAR-T
CB-011
Flag link:
FDA places partial hold on Molecular Templates’ Phase I trial
FDA places partial hold on Molecular Templates’ Phase I trial
Clinical Trials Arena
Molecular Templates
MT-0169
Multiple Myeloma
clinical trials
Flag link:
This Cancer Drug Candidate Could Be a Hit for Pfizer
This Cancer Drug Candidate Could Be a Hit for Pfizer
Motley Fool
Pfizer
elranatamab
Multiple Myeloma
Flag link:
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Fierce Pharma
Bristol Myers Squibb
Abecma
CAR-T
Multiple Myeloma
Flag link:
J&J, Legend’s cancer cell therapy has early success in key clinical trial
J&J, Legend’s cancer cell therapy has early success in key clinical trial
BioPharma Dive
JNJ
Legend Biotech
Carvykti
Multiple Myeloma
clinical trials
cell therapy
Flag link:
Sales of J&J, Legend cell therapy plateau amid production challenges
Sales of J&J, Legend cell therapy plateau amid production challenges
BioPharma Dive
JNJ
Legend Biotech
gene therapy
Carvykti
Multiple Myeloma
Flag link:
ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?
Fierce Pharma
Bristol Myers Squibb
ASH 2022
Abecma
clinical trials
Multiple Myeloma
Flag link:
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
Flag link:
ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets
ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets
Fierce Biotech
ASH 2022
Gracell
CAR-T
Multiple Myeloma
Bristol Myers Squibb
Pfizer
Flag link:
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Fierce Biotech
Gilead Sciences
Kite Pharma
Arcellx
clinical trials
Multiple Myeloma
cell therapy
JNJ
Legend Biotech
Flag link:
FDA looks to pull approval for Oncopeptides' troubled multiple myeloma drug Pepaxto
FDA looks to pull approval for Oncopeptides' troubled multiple myeloma drug Pepaxto
Fierce Pharma
Oncopeptides
Multiple Myeloma
Pepaxto
FDA
Flag link:
GSK to pull blood cancer drug from US market after study failure
GSK to pull blood cancer drug from US market after study failure
BioPharma Dive
GSK
blood cancer
Blenrep
clinical trials
Multiple Myeloma
Flag link:
Time for GSK to stop dreaming about Blenrep
Time for GSK to stop dreaming about Blenrep
EP Vantage
GSK
BCMA
Blenrep
clinical trials
Multiple Myeloma
Flag link:
J&J nabs FDA okay for BCMA bispecific Tecvayli
J&J nabs FDA okay for BCMA bispecific Tecvayli
Pharmaphorum
JNJ
Multiple Myeloma
Tecvayli
FDA
Flag link:
FDA advisory committee issues back to back negative votes on two cancer drugs
FDA advisory committee issues back to back negative votes on two cancer drugs
MedCity News
FDA
Spectrum Pharmaceuticals
Oncopeptides
clinical trials
poziotinib
Pepaxto
Multiple Myeloma
Flag link:
Despite being approved in Europe, Oncopeptides' Pepaxto will remain sidelined in the US
Despite being approved in Europe, Oncopeptides' Pepaxto will remain sidelined in the US
Fierce Pharma
FDA
Oncopeptides
Multiple Myeloma
Pepaxto
Flag link:
Janssen reports Phase II data for Darzalex-RVd to treat multiple myeloma
Janssen reports Phase II data for Darzalex-RVd to treat multiple myeloma
Clinical Trials Arena
JNJ
Janssen
clinical trials
Darzalex
Revlimid
Velcade
Multiple Myeloma
Flag link:
J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
Fierce Pharma
JNJ
Europe
bispecific antibodies
Multiple Myeloma
Tecvayli
teclistamab
Flag link:
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
BioPharma Dive
Bristol Myers Squibb
2seventy bio
Abecma
CAR-T
Multiple Myeloma
Flag link:

Pages